cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
Company profile
Ticker
CGTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
COGNITION THERAPUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Cognition Therapeutics PTY LTD ...
CGTX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
26 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
424B5
Prospectus supplement for primary offering
13 Mar 24
8-K
Results of Operations and Financial Condition
11 Mar 24
424B5
Prospectus supplement for primary offering
11 Mar 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
EFFECT
Notice of effectiveness
9 Jan 24
424B4
Prospectus supplement with pricing info
8 Jan 24
Latest ownership filings
4
Lisa Ricciardi
14 Mar 24
4
John Brendan Doyle
20 Feb 24
4
Anthony Caggiano
20 Feb 24
4
Lisa Ricciardi
20 Feb 24
4
Anthony Caggiano
9 Feb 24
4
Lisa Ricciardi
9 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
PATHSTONE FAMILY OFFICE, LLC
19 Jan 24
SC 13D/A
BIOS Memory SPV I, LP
13 Nov 23
3
Initial statement of insider ownership
13 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.97 mm | 32.97 mm | 32.97 mm | 32.97 mm | 32.97 mm | 32.97 mm |
Cash burn (monthly) | 1.41 mm | 1.14 mm | 4.92 mm | 3.74 mm | 1.39 mm | 1.73 mm |
Cash used (since last report) | 8.38 mm | 6.77 mm | 29.27 mm | 22.25 mm | 8.26 mm | 10.30 mm |
Cash remaining | 24.59 mm | 26.20 mm | 3.70 mm | 10.72 mm | 24.71 mm | 22.67 mm |
Runway (months of cash) | 17.5 | 23.0 | 0.8 | 2.9 | 17.8 | 13.1 |
Institutional ownership, Q2 2023
37.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 6 |
Closed positions | 5 |
Increased positions | 7 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 12.38 bn |
Total shares | 14.62 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BIOS Memory SPV I | 5.50 mm | $7.98 mm |
Pathstone Family Office | 2.21 mm | $4.04 bn |
AIGH Capital Management | 2.04 mm | $3.73 bn |
Hirschman Orin | 2.04 mm | $0.00 |
Vanguard | 668.43 k | $1.22 bn |
Worth Venture Partners | 508.72 k | $930.96 mm |
Carlson Capital L P | 245.00 k | $448.35 mm |
Perigon Wealth Management | 223.50 k | $409.01 mm |
AFG American Financial | 205.00 k | $375.00 k |
Geode Capital Management | 176.50 k | $322.99 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Lisa Ricciardi | Common Stock | Buy | Acquire P | No | No | 1.75 | 5,700 | 9.98 k | 291,345 |
3 Feb 24 | Anthony Caggiano | Common Stock | Payment of exercise | Dispose F | No | No | 2.29 | 12,777 | 29.26 k | 81,629 |
3 Feb 24 | Lisa Ricciardi | Common Stock | Payment of exercise | Dispose F | No | No | 2.29 | 27,828 | 63.73 k | 210,645 |
8 Nov 23 | Leslie W. Kreis | Common Stock | Grant | Acquire A | Yes | No | 1.05 | 500,095 | 525.10 k | 500,095 |
News
Oppenheimer Maintains Outperform on Cognition Therapeutics, Maintains $9 Price Target
27 Mar 24
Cognition Therapeutics Q4 EPS $(0.27) Beats $(0.34) Estimate
26 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
A Preview Of Cognition Therapeutics's Earnings
25 Mar 24
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
15 Mar 24
Press releases
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
26 Mar 24
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
15 Mar 24
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
11 Mar 24
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies
6 Mar 24
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
6 Feb 24